Prosecution Insights
Prosecution Insights
5 pending office actions • 1 client • 4 examiners • 3 art units • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| §112 only | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGA, KYLE THOMAS | 2 | 62.4% | +43.9% |
| BREEN, KIMBERLY CATHERINE | 1 | 26.0% | +58.6% |
| YU, DAVID TUYANG | 1 | — | — |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 56.5% | +36.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18486913 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | BREEN, KIMBERLY CATHERINE | 70d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430289 | SPLICE ACCEPTOR SITE DISRUPTION OF A DISEASE-ASSOCIATED GENE USING ADENOSINE DEAMINASE BASE EDITORS, INCLUDING FOR THE TREATMENT OF GENETIC DISEASE | REGA, KYLE THOMAS | 91d overdue |
| 18486913 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | BREEN, KIMBERLY CATHERINE | 70d overdue |
| 17430669 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | REGA, KYLE THOMAS | 24d overdue |
| 17430274 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | DACE DENITO, ALEXANDRA GERALDINE | 70d |
| Client (Assignee) | Pending OAs |
|---|---|
| BEAM THERAPEUTICS INC. | 5 |
| Art Unit | Apps |
|---|---|
| 1636 | 3 |
| 1657 | 1 |
| 1635 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18486913 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | BEAM THERAPEUTICS INC. | BREEN, KIMBERLY CATHERINE | 1657 | §103 | Non-Final OA | 70d overdue | Pending | Oct 13, 2023 |
| 18031547 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | BEAM THERAPEUTICS INC. | YU, DAVID TUYANG | 1635 | Other | Non-Final OA | 23d overdue | Pending | Apr 12, 2023 |
| 17430669 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | BEAM THERAPEUTICS INC. | REGA, KYLE THOMAS | 1636 | §103 | Non-Final OA | 24d overdue | Pending | Aug 12, 2021 |
| 17430289 | SPLICE ACCEPTOR SITE DISRUPTION OF A DISEASE-ASSOCIATED GENE USING ADENOSINE DEAMINASE BASE EDITORS, INCLUDING FOR THE TREATMENT OF GENETIC DISEASE | BEAM THERAPEUTICS INC. | REGA, KYLE THOMAS | 1636 | §112 | Final Rejection | 91d overdue | Pending | Aug 11, 2021 |
| 17430274 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | BEAM THERAPEUTICS INC. | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | 70d | Pending | Aug 11, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial